StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Abiraterone

HCID 132971
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
154229-19-3
Standard-SMILES
C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12
InChIKey
GZOSMCIZMLWJML-VJLLXTKPSA-N
Summenformel
C24H31NO
Durchschnittliche Molmasse
349,5 g/mol
Monoisotopische Masse
349,24056461

Überblick

Abiraterone is a 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cancer. It has a role as an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a 3beta-hydroxy-Delta(5)-steroid, a member of pyridines and a 3beta-sterol. It derives from a hydride of an androstane.

Namen und Bezeichner

Bevorzugter Name
Abiraterone
IUPAC
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
Englischer Name
Abiraterone
Summenformel
C24H31NO
Molmasse
349.52

Namen und Synonyme

Abiraterone154229-19-3CB 7598CB-759817-(3-Pyridyl)androsta-5,16-dien-3beta-olAbirateronaabirateronumCB759817-(pyridin-3-yl)androsta-5,16-dien-3beta-ol(3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-olAndrosta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
Weitere Namen anzeigen
(3S,8R,9S,10R,13S,14S)-10,13-diMethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-olAberration7-Keto Abiraterone Acetate(3β)-17-(3-Pyridinyl)androsta-5,16-dien-3-olCS-211AbironAbytron
G819A456D0NSC-741232CHEBI:68642DTXSID80879993(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta(a)phenanthren-3-olRefChem:57133L02BX03DTXCID501021626

Datenbank-Bezeichner

CAS
154229-19-3
PubChem CID
132971
DTXSID
DTXSID80879993
ChEMBL
CHEMBL254328
ChEBI
CHEBI:68642
UNII
G819A456D0
EC Number
810-941-6
Nikkaji
J617.457D

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,6
Polarare Oberfläche (TPSA)
33,1 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
1
Schwere Atome
26
Formalladung
0
Komplexität
636

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Metabolite of Abiraterone acetate

Pharmaceuticals -> Listed in ZINC15

Human DrugsHormones and antihormones
Endocrine DisruptorsPotential endocrine disrupting compound

Physikochemische Eigenschaften

Schmelzpunkt
227 · 227-228 °C(Solv: toluene (108-88-3))
Siedepunkt
500.2 · 500.2±50.0 °C(Predicted)
Dichte
1.14 · 1.14±0.1 g/cm3(Predicted)
storage temp.
2 · 2-8°C
Löslichkeit
Chloroform (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
14.71 · 14.71±0.70(Predicted)
Farbe
White to Pale Yellow
InChIKey
GZOSMCIZMLWJML-DROLTIPTNA-N
SMILES
C[C@]12CC[C@]3([H])[C@]4(CC[C@H](O)CC4=CC[C@@]3([H])[C@]1([H])CC=C2C1=CN=CC=C1)C |&1:1,4,6,9,15,17,r|
CAS Datenbank
154229 · 154229-19-3

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H360 (57.1%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P273, P280, P318, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 7 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationREACH registered substance: (1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵] heptadeca-7,13-dien-5-ol (EC: 810-941-6)
Hazard Classes and CategoriesRepr. 1B (57.1%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Serum aminotransferase elevations occur in up to 13% of patients treated with abiraterone compared with 1% to 8% receiving placebo or a comparator drug, but the abnormalities are generally mild, transient and not associated with symptoms or jaundice. ALT elevations above 5 times the upper limit of normal (ULN) occur in 6% of abiraterone treated vs

Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Abiraterone

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 4 Einträge

L02BX03

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

L02BX03

Protein BindingAbiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
Pharmacodynamics · 1 Eintrag

_In vivo_, abiraterone acetate is rapidly hydrolyzed to abiraterone, which mediates its pharmacological actions. Abiraterone decreases serum testosterone and other androgens. A change in serum prostate-specific antigen (PSA) levels may be observed.

Mechanism of Action · 1 Eintrag

17α-hydroxylase/C17,20-lyase (CYP17) is a key enzyme in androgen biosynthesis. It is primarily expressed in testicular, adrenal, and prostatic tumours. CYP17 catalyzes the 17α-hydroxylation of pregnenolone and progesterone to their 17α-hydroxy derivative, followed by subsequent cleavage of the C 20,21-acetyl group to yield dehydroepiandrosterone (DHEA) and androstenedione. DHEA and androstenedione are precursors of testosterone. Aberrant androgen levels and unregulated androgen receptor signalling have been implicated in the development and progression of various prostate cancers. Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour. Abiraterone inhibits CYP17 to block androgen production. Inhibition of CYP17 can also result in increased mineralocorticoid production by the adrenals.

Biological Half-LifeIn patients with mCRPC, the mean (± SD) terminal half-life of abiraterone in plasma is 12 (± 5) hours.
Metabolism/Metabolites · 2 Einträge

The conversion of abiraterone acetate to abiraterone, the active metabolite, is likely to be mediated by esterases, although specific esterases have not been identified. In human plasma, the two main circulating metabolites are abiraterone sulfate, which is formed by CYP3A4 and SULT2A1, and N-oxide abiraterone sulfate, which is formed by SULT2A1. These metabolites each account for about 43% of abiraterone exposure and are pharmacologically inactive.

Abiraterone has known human metabolites that include abiraterone sulfate.

FDA Pharmacological Classification · 6 Einträge

G819A456D0

ABIRATERONE

Mechanisms of Action [MoA] - Cytochrome P450 17A1 Inhibitors

Established Pharmacologic Class [EPC] - Cytochrome P450 17A1 Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 2D6 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C8 Inhibitors

Absorption, Distribution and Excretion · 3 Einträge

Geometric mean (± SD) Cmax was 73 (± 44) ng/mL and AUC0-∞ was 373 (± 249) ng x hr/mL following a single dose of 500 mg abiraterone acetate in overnight-fasted healthy subjects. Dose proportionality was observed in single doses of abiraterone acetate ranging from 125 mg to 625 mg. A group of patients with mCRPC received a daily dose of 1,000 mg: at steady-state, the mean (± SD) Cmax was 226 (± 178) ng/mL and AUC was 993 (± 639) ng x hr/mL. Following oral administration of abiraterone acetate to patients with metastatic castration-resistant prostate cancer, the median Tmax was two hours. _In vivo_, abiraterone acetate is converted to abiraterone. In clinical studies of other abiraterone acetate formulations, abiraterone acetate plasma concentrations were below detectable levels (< 0.2 ng/mL) in > 99% of the analyzed samples. Systemic exposure to abiraterone is increased when abiraterone acetate is administered with food. Abiraterone Cmax was approximately 6.5-fold higher, and AUC0-∞ was 4.4-fold higher when a single dose of abiraterone acetate 500 mg was administered with a high-fat meal (56-60% fat, 900-1,000 calories) compared to overnight fasting in healthy subjects. Given the normal variation in the content and composition of meals, taking abiraterone with meals has the potential to result in increased and highly variable exposures.

Following oral administration of <sup>14</sup>C-abiraterone acetate, approximately 88% of the radioactive dose is recovered in feces: the major compounds present in feces are unchanged abiraterone acetate and abiraterone, accounting for approximately 55% and 22% of the administered dose, respectively. Approximately 5% of the dose is recovered in urine.

The mean (± SD) apparent steady-state volume of distribution is 19,669 (± 13,358) L.

Anwendungen · 2 Einträge

HistoryAbiraterone (brand name: Zytiga) is an anti-cancer drug developed by Centocor Ortho Biotech Inc. It was first approved by the FDA on 28 April 2011 for the treatment of advanced prostate cancer. In December 2012, the FDA expanded Zytiga's approved use to include treatment of men with advanced (metastatic) castration-resistant prostate cancer prior to chemotherapy. By February 2018, the FDA further approved Zytiga (abiraterone acetate) in combination with prednisone for the treatment of early metastatic prostate cancer.

VerwendenAbiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

NatriumcarbonatDichlorobis(triphenylphosphin)palladiumNatriumhydroxidHydrogenchloridDiethyl(3-pyridyl)borane

Nachgelagerte Produkte

Abiraterone acetate

Ergänzende Hinweise

DefinitionChEBI: A 3beta-sterol that is androsta-5,16-dien-3beta-ol substituted at position 17 by a 3-pyridyl group. Administered as the O-acetate, it is used for treatment of metastatic castrate-resistant prostate cance .

Zugehörige Reaktionen

14
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 53180
HRID 53180als Produkt
Reaktionsgleichung von HRID 53189
HRID 53189als Produkt
Reaktionsgleichung von HRID 53190
HRID 53190als Edukt
Reaktionsgleichung von HRID 348776
HRID 348776als Produkt
Reaktionsgleichung von HRID 525309
HRID 525309als Edukt
Reaktionsgleichung von HRID 531211
HRID 531211als Edukt
Reaktionsgleichung von HRID 531212
HRID 531212als Edukt
Reaktionsgleichung von HRID 531213
HRID 531213als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung